BRIEF-Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC

Verastem

Verastem

VSTM

0.00

June 3 (Reuters) - Verastem Inc VSTM.O:

  • VERASTEM ONCOLOGY ANNOUNCES U.S. FDA FAST TRACK DESIGNATION FOR VERSUS-7375, AN ORAL AND POTENTIAL BEST-IN-CLASS INVESTIGATIONAL KRAS G12D (ON/OFF) INHIBITOR FOR THE TREATMENT OF KRAS G12D-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

  • VERASTEM - INITIATES PHASE 2 TARGET-D 202 TRIAL FOR ADVANCED NSCLC

Source text: ID:nBw8Zw7mXa

Further company coverage: VSTM.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.